Market Overview

Sensei Biotherapeutics Appoints Ildiko Csiki, M.D., Ph.D., as Chief Medical Officer

Share:

Sensei Biotherapeutics, Inc., a privately-held biopharmaceutical company
developing immuno-oncology therapies that teach the immune system to
recognize and attack cancer, today announced the appointment of Ildiko
Csiki, M.D., Ph.D., as Chief Medical Officer. Dr. Csiki brings nearly
two decades of leadership experience in oncology drug development and
research, most recently serving as Vice of President of Immuno-Oncology
Clinical Development at Inovio Pharmaceuticals.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180821005189/en/

Sensei CMO Ildiko Csiki (Photo: Business Wire)

Sensei CMO Ildiko Csiki (Photo: Business Wire)

"It is with great excitement that we welcome such an accomplished
oncologist and clinical leader to Sensei. Ildiko brings an outstanding
intellect, expertise and passion for patients to our team," said John
Celebi, CEO of Sensei Biotherapeutics. "She is joining Sensei at a time
when we are taking bold steps in discovering and developing the next
generation of cancer immunotherapies, and we look forward to her
contributions to building our oncology drug development capabilities and
developing the clinical strategies for SNS-301 and the other programs in
our pipeline."

Dr. Csiki joins Sensei at a pivotal time with promising clinical data
from the Phase I trial of its lead drug candidate SNS-301 expected in
the fall of 2018, and the continued development of its proprietary
SPIRIT drug development platform that is generating a pipeline of
innovative immuno-oncology therapies.

"I am excited to join Sensei and have the opportunity to play a
leadership role in advancing innovative immuno-oncology drug candidates
and bring new medicines to cancer patients," said Ildiko Csiki, CMO of
Sensei Biotherapeutics "Our SPIRIT platform offers an innovative
mechanism for detecting and eliminating cancer. I am eager to move
forward with the clinical program for Sensei's lead drug candidate,
SNS-301, as well as creating the clinical strategy for the company's
pipeline of immuno-oncology therapies with the potential to have a
profound impact for cancer patients."

In her most recent role, Dr. Csiki served as Vice of President of
Immuno-Oncology Clinical Development at Inovio Pharmaceuticals where she
led the advancement of Inovio's DNA-based cancer immunotherapies based
on T cell immunotherapeutic vaccines, including responsibility for
overseeing clinical programs, clinical strategy, medical monitoring and
regulatory submissions. Previously, Dr. Csiki was a Senior Director of
Oncology Clinical Development at Merck, as a clinical development lead
for pembrolizumab (Keytruda®), and she was Director of Clinical
Development at GSK focused on a lymphoma and other oncology programs.
Before that, Dr. Csiki was an Assistant Professor in the Perelman Cancer
Center at the University of Pennsylvania where she had an active
clinical practice and a translational science laboratory focused on
thoracic malignancies. She holds an M.D. and Ph.D. from Vanderbilt
University School of Medicine. Her postdoctoral training included an
internship in Internal Medicine and residency in radiation oncology at
Vanderbilt and subsequently, a Holman Pathway Research Fellowship.

About Sensei Biotherapeutics

Sensei Biotherapeutics is a privately-held biopharmaceutical company
developing immuno-oncology therapies that stimulate the immune system to
‘teach' it to recognize cancer-specific antigens and attack cancer
cells. The company's patented and proprietary technology platform,
called SPIRIT, creates novel therapies that target Tumor Specific
Antigens (TSAs) – including neoantigens or selective self-antigens –
that are designed to overcome immune tolerance by eliciting a potent
cellular and humoral immune response to eliminate cancer cells. With
leading-edge technology for the discovery of TSAs, Sensei's precision
medicine approach to immuno-oncology includes developing novel cancer
vaccines and CAR-T therapies along with companion diagnostics. The
company's lead drug candidate, SNS-301, is a first-in-class cancer
vaccine that targets a novel embryonic self-antigen and has successfully
completed a Phase 1 clinical study. Sensei Biotherapeutics is located in
Gaithersburg, MD. For more information, please visit www.senseibio.com.

View Comments and Join the Discussion!